| Literature DB >> 26096678 |
Arun K Ghosh1, Jun Takayama2, Luke A Kassekert2, Jean-Rene Ella-Menye2, Sofiya Yashchuk2, Johnson Agniswamy3, Yuan-Fang Wang3, Manabu Aoki4, Masayuki Amano4, Irene T Weber3, Hiroaki Mitsuya5.
Abstract
We describe the design, synthesis and biological evaluation of a series of novel HIV-1 protease inhibitors bearing isophthalamide derivatives as the P2-P3 ligands. We have investigated a range of acyclic and heterocyclic amides as the extended P2-P3 ligands. These inhibitors displayed good to excellent HIV-1 protease inhibitory activity. Also, a number of inhibitors showed very good antiviral activity in MT cells. Compound 5n has shown an enzyme Ki of 0.17 nM and antiviral IC50 of 14 nM. An X-ray crystal structure of inhibitor 5o-bound to HIV-1 protease was determined at 1.11Å resolution. This structure revealed important molecular insight into the inhibitor-HIV-1 protease interactions in the active site.Entities:
Keywords: Antiviral; Design; HIV-1 protease; Inhibitors; Isophthalamide; Synthesis
Mesh:
Substances:
Year: 2015 PMID: 26096678 PMCID: PMC4607586 DOI: 10.1016/j.bmcl.2015.05.052
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN: 0960-894X Impact factor: 2.823